FDA
-
-
-
-
-
-
-
T2 Biosystems (TTOO) Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens
-
-
-
-
-
-
-
T2 Biosystems (TTOO) Announces Preliminary Third Quarter 2024 Financial Results
-
-
-
-
-
-
-
T2 Biosystems Provides Updates on its New Product Development Pipeline Progress
-
-
-
-
-
-
-
T2 Biosystems (TTOO) Regains Compliance with Nasdaq Continued Listing Requirements
-
-
-
-
-
-
-
T2 Biosystems Announces Letter of Intent to Enter Strategic Partnership for Lyme Disease
-
-
-
-
-
-
-
T2 Biosystems Shareholders Vote for CRG Debt Conversion into Equity
-
-
-
-
-
-
-
T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

